Want FREE Templates on Digital Transformation? Download our FREE compilation of 50+ slides. This is an exclusive promotion being run on LinkedIn.

Pharma Disease Insights: Multiple Myeloma   29-slide PPT PowerPoint presentation (PPTX)
$99.00

Pharma Disease Insights: Multiple Myeloma (29-slide PPT PowerPoint presentation (PPTX)) Preview Image Pharma Disease Insights: Multiple Myeloma (29-slide PPT PowerPoint presentation (PPTX)) Preview Image Pharma Disease Insights: Multiple Myeloma (29-slide PPT PowerPoint presentation (PPTX)) Preview Image Pharma Disease Insights: Multiple Myeloma (29-slide PPT PowerPoint presentation (PPTX)) Preview Image Pharma Disease Insights: Multiple Myeloma (29-slide PPT PowerPoint presentation (PPTX)) Preview Image Pharma Disease Insights: Multiple Myeloma (29-slide PPT PowerPoint presentation (PPTX)) Preview Image Pharma Disease Insights: Multiple Myeloma (29-slide PPT PowerPoint presentation (PPTX)) Preview Image Pharma Disease Insights: Multiple Myeloma (29-slide PPT PowerPoint presentation (PPTX)) Preview Image Pharma Disease Insights: Multiple Myeloma (29-slide PPT PowerPoint presentation (PPTX)) Preview Image Log in to unlock full preview.
Arrow   Unlock all 11 preview images:   Login Register

Pharma Disease Insights: Multiple Myeloma (PowerPoint PPTX)

File Type: 29-slide PPT PowerPoint presentation (PPTX)

$99.00

Add to Cart
  


BUY WITH CONFIDENCE

Immediate digital download upon purchase.
Lifetime document updates included with purchase.
Fully editable & customizable PPTX document.
Trusted by over 10,000+ organizations.

DESCRIPTION

This product (Pharma Disease Insights: Multiple Myeloma) is a 29-slide PPT PowerPoint presentation (PPTX), which you can download immediately upon purchase.

The multiple myeloma market will witness an impressive 10% annual growth over 2015-2025, with major-market sales increasing from $8.6 billion in 2015 to $22.3 billion in 2025. Growth will be fueled by the continued uptake and label expansions of current therapies and the expected market entry of four novel, premium-priced therapies. Immunomodulatory agents are, and will remain, the dominant drug class throughout the forecast period and will capture more than 50% of major-market sales in 2025.

Currently approved therapies will continue to have a meaningful impact on the multiple myeloma treatment algorithm and market sales. Lenalidomide is set to retain its position as the sales-leading agent in multiple myeloma, with sales expected to reach more than $11.7 billion across the seven major markets in 2025. Continued penetration of the R/R setting will provide significant revenue, as will its label expansion in the first-line setting, in addition to use in combination with recently approved and emerging agents, such as carfilzomib, ixazomib, elotuzumab, daratumumab, and pembrolizumab.

INTRODUCTION
1. Key Findings
2. Market Share of Colorectal Cancer Drug Classes in 2015 and 2025
3. Disease Market SWOT Analysis
ETIOLOGY AND PATHOPHYSIOLOGY
1. Key Findings
2. Expert Insight
3. Disease Overview
4. Disease Pathophysiology
5. Etiology
6. Pathophysiology
KEY PATHWAYS AND DRUG TARGETS
MARKET OUTLOOK
1. Key Findings
2. Expert Insight
3. Market Overview
4. What Factors Are Driving the Market
5. What Factors Are Constraining the Market

Got a question about the product? Email us at support@flevy.com or ask the author directly by using the "Ask the Author a Question" form. If you cannot view the preview above this document description, go here to view the large preview instead.

Source: Best Practices in Cancer PowerPoint Slides: Pharma Disease Insights: Multiple Myeloma PowerPoint (PPTX) Presentation, BigPharma2000


$99.00

Add to Cart
  

OVERVIEW

File Type: PowerPoint pptx (PPTX)
File Size: 1.9 MB
Number of Slides: 29 (includes cover and all slides)


ABOUT THE AUTHOR

Author: BigPharma2000
Additional documents from author: 40

Ask the Author a Question

Must be logged in

Did you know?
The average daily rate of a McKinsey consultant is $6,625 (not including expenses). The average price of a Flevy document is $65.
Bundle and save! You can save up to % with bundles!

View bundle(s)




Trusted by over 10,000+ Client Organizations
Since 2012, we have provided best practices to over 10,000 businesses and organizations of all sizes, from startups and small businesses to the Fortune 100, in over 130 countries.
AT&T GE Cisco Intel IBM Coke Dell Toyota HP Nike Samsung Microsoft Astrazeneca JP Morgan KPMG Walgreens Walmart 3M Kaiser Oracle SAP Google E&Y Volvo Bosch Merck Fedex Shell Amgen Eli Lilly Roche AIG Abbott Amazon PwC T-Mobile Broadcom Bayer Pearson Titleist ConEd Pfizer NTT Data Schwab




Read Customer Testimonials




Save with Bundles

This document is available as part of the following discounted bundle(s):

Save %!
Pharma Disease Insights: Oncology

This bundle contains 5 total documents. See all the documents to the right.

$299.00


Add Bundle & Save



Customers Also Like These Documents

Related Management Topics


Healthcare Cancer ESG Integrated Financial Model

Download our FREE Strategy & Transformation Framework Templates

Download our free compilation of 50+ Strategy & Transformation slides and templates. Frameworks include McKinsey 7-S Strategy Model, Balanced Scorecard, Disruptive Innovation, BCG Experience Curve, and many more.